<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Melanoma and pregnancy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Melanoma and pregnancy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Melanoma and pregnancy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marcia S Driscoll, MD, PharmD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer A Stein, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jane M Grant-Kels, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael B Atkins, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hensin Tsao, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1337351582"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Approximately one-third of females diagnosed with melanoma are of childbearing age [<a href="#rid1">1</a>], and a 2015 Swedish population-based cancer registry study found that melanoma was the most common malignancy in pregnancy [<a href="#rid2">2</a>].</p><p>There is continuing controversy concerning the prognosis of patients diagnosed with melanoma during pregnancy. Initial concerns about pregnancy's impact on prognosis in patients diagnosed with melanoma date back to case reports which suggested that pregnancy might lead to transformation of nevi into melanomas, increase the growth rate of existing melanomas, and cause localized melanomas to metastasize [<a href="#rid3">3,4</a>]. Subsequently, multiple observations seemed to support the argument that melanoma is a hormonally responsive malignancy: changes in skin pigmentation during pregnancy, detection of hormone receptors on some melanomas using older technology, a higher incidence of melanoma after puberty, and relative immunosuppression during pregnancy [<a href="#rid5">5-8</a>].</p><p>The management of patients diagnosed with melanoma during pregnancy is likewise controversial, particularly concerning sentinel lymph node biopsy (SLNB) and decisions about the management of the patient with nodal or metastatic disease [<a href="#rid9">9</a>].</p><p>This topic will review the data that address prognosis for those diagnosed with melanoma before, during, and after pregnancy. In addition, this topic will address management, including initial biopsy of suspected melanoma, wide local excision, SLNB, and decision-making concerning the use of subsequent hormonal therapy and future pregnancy.</p><p>The general approach to cutaneous melanoma is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7620.html" rel="external">"Surgical management of primary cutaneous melanoma or melanoma at other unusual sites"</a> and  <a class="medical medical_review" href="/z/d/html/85841.html" rel="external">"Overview of the management of advanced cutaneous melanoma"</a>.)</p><p class="headingAnchor" id="H2885659465"><span class="h1">PROGNOSIS OF PREGNANCY-ASSOCIATED MELANOMA</span></p><p class="headingAnchor" id="H4249129067"><span class="h2">Study limitations</span><span class="headingEndMark"> — </span>Multiple studies have looked at the relationship between pregnancy and cutaneous melanoma. Factors limiting the interpretation of the literature include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Many of the case series prior to the 1980s did not account for the most important prognostic factors, such as depth of tumor or stage of disease. Subsequently, there have been a number of small case-control studies and large population-based cohort studies. While the case-control studies have the advantage of including important prognostic factors, the small numbers of patients included are an important limitation. Conversely, the larger cohort studies lack complete data on staging and Breslow depth.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some of the larger studies do not distinguish between diagnosis of melanoma during pregnancy and diagnosis during the postpartum period. Such studies refer to these patients as having pregnancy-associated melanoma (PAM). The definition of PAM varies in different studies and ranges from diagnosis during pregnancy to diagnosis up to five years after delivery [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is significant variability in the techniques and quality of the statistical analysis of the data between studies and in the presence of age-matched nonpregnant control groups, as well as a lack of consideration of important confounding factors, including but not limited to age, anatomic site of lesion, sun exposure or season at time of diagnosis, depth of the melanoma, absence or presence of ulceration, and presence as well as number of mitoses per mm<sup>2</sup>.</p><p></p><p class="headingAnchor" id="H2327232283"><span class="h2">Diagnosis during pregnancy</span><span class="headingEndMark"> — </span>Most of the multiple small controlled studies [<a href="#rid11">11-17</a>] and large population-based cohort studies [<a href="#rid10">10,18-21</a>] do not show a negative influence of pregnancy on survival.</p><p class="bulletIndent1"><span class="glyph">●</span>An example of one population-based study is a Swedish registry-based study, which compared cause-based mortality in 1019 females with PAM (defined as melanoma diagnosis during pregnancy through the period up to two years postpartum) with females diagnosed with melanoma who did not become pregnant during a comparable period of time [<a href="#rid10">10</a>]. When focused upon females diagnosed with melanoma during pregnancy, the PAM group was comprised of 247 females, which had no significant difference in mortality (hazard ratio [HR] 0.79, 95% CI 0.44-1.41) when adjusted for pertinent prognostic factors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a review of 10 case-control studies that included 185 females diagnosed with melanoma during pregnancy and 5348 females of the same childbearing age who were diagnosed with melanoma but were not pregnant, pregnancy did not have an impact on survival and did not increase the risk of a second melanoma [<a href="#rid18">18</a>]. The higher the parity and the younger the age of the mother at her first delivery, the lower the risk of melanoma. Thus, the authors concluded that there was no reason for physicians to recommend deferral of subsequent pregnancies in females who have been diagnosed with a stage I melanoma during a previous pregnancy [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A controversial study is a single-institution study that compared 41 females diagnosed with PAM with a control group of females of childbearing age who were not pregnant within one year of diagnosis [<a href="#rid17">17</a>]. PAM was defined as melanoma diagnosis either during pregnancy or within one year after delivery. After adjustment for stage, age, and location, the PAM group showed a five-, seven-, and ninefold increase in mortality, metastasis, and recurrence, respectively, when compared with controls.</p><p></p><p class="bulletIndent1">However, in this study, the number of relevant patients in the PAM group becomes much smaller since melanoma in situ cases comprised 50 percent of the PAM group [<a href="#rid17">17</a>]. More importantly, there is inconsistent reporting of staging information in the paper such that the authors report double the cases of advanced disease in the PAM group later in the manuscript compared with an earlier statement in the text, thus profoundly affecting their analysis due to the small number of cases.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A single-institution study identified patients diagnosed with melanoma during pregnancy from a prospectively maintained database from January 1971 through May 2016. When 155 patients with PAM were compared with matched (by Breslow thickness, age, stage, and ulceration status), non-PAM controls, there were no significant differences in disease-free survival, overall survival, or melanoma-specific survival [<a href="#rid22">22</a>].</p><p></p><p class="headingAnchor" id="H1605535905"><span class="h2">Diagnosis postpartum</span><span class="headingEndMark"> — </span>Multiple observational studies [<a href="#rid2">2,10,15,20,21,23</a>] have generally found no influence on prognosis when melanoma is diagnosed up to five years following delivery. However, other studies suggested an increased risk of death from melanoma in the first year postpartum, which may be due to delayed diagnosis during pregnancy [<a href="#rid2">2,23,24</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a Swedish registry study, 1019 females were diagnosed with PAM, which is defined as a melanoma diagnosis during pregnancy and up to five years postpartum [<a href="#rid10">10</a>]. When the melanoma diagnosis in each postpartum year is evaluated independently from diagnosis during pregnancy, there was no evidence of a negative impact on survival when evaluating HRs for each year postpartum; PAM groups in each year included approximately 200 to 300 cases and more than 10,000 controls.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>By contrast, a retrospective English study that linked data from a national cancer registry and hospital discharge data evaluated patients diagnosed with melanoma up to five years postpartum [<a href="#rid23">23</a>]. There was a significantly increased death rate in the first year after delivery (HR 1.92, 95% CI 1.32-2.79) but not in the four subsequent years postpartum. Another study found a lower incidence of melanoma diagnosed during pregnancy than expected compared with the first six months postpartum [<a href="#rid2">2</a>]. The spike in melanoma diagnosis and death in the early postpartum period may be caused by a delay in diagnosis.</p><p></p><p class="headingAnchor" id="H3479165919"><span class="h2">Diagnosis prior to pregnancy</span><span class="headingEndMark"> — </span>Few studies have addressed the impact on prognosis when melanoma is diagnosed before a patient becomes pregnant, but based upon the available data, there does not appear to be an effect on prognosis [<a href="#rid11">11,15,18</a>]. In a large Swedish retrospective cohort study [<a href="#rid18">18</a>], 966 females who had pregnancies after a diagnosis of a primary melanoma were compared with 4567 females who did not become pregnant after diagnosis. After adjustment for Breslow depth, tumor site, Clark level, and age, pregnancy did not significantly affect survival (HR 0.58, 95% CI 0.32-1.05).</p><p>For patients with a history of melanoma and multiple dysplastic nevi, we suggest more frequent dermatology examinations during pregnancy.</p><p class="headingAnchor" id="H2124646361"><span class="h1">MANAGEMENT OF MELANOMA DURING PREGNANCY</span><span class="headingEndMark"> — </span>The evaluation and management of the pregnant patient are similar to that of the nonpregnant patient and are based upon stage of disease. However, there are potential concerns that arise even in the initial biopsy of suspected melanoma. As the stage of disease becomes more advanced, evaluation and management decisions become more complex in order to ensure safety of the mother and the fetus.</p><p class="headingAnchor" id="H196436164"><span class="h2">Initial biopsy</span><span class="headingEndMark"> — </span>A changing pigmented lesion during pregnancy that is clinically and dermatoscopically of concern as a possible melanoma should be biopsied immediately, as it would be in a nonpregnant patient. Excisional biopsy is the optimal way to evaluate a primary cutaneous melanoma.</p><p>The use of local anesthesia should be considered more carefully in the pregnant female. <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">Lidocaine</a> is considered safe for use in pregnancy "in small amounts" by the American Academy of Dermatology (AAD) 2016 Guidelines for the Use of Local Anesthesia in Office-Based Dermatologic Surgery [<a href="#rid25">25</a>]. Under the new US Food and Drug Administration (FDA) pregnancy guidelines for lidocaine, lidocaine "may use during pregnancy; risk of fetal harm not expected based on limited human data."</p><p>The addition of <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a> as a vasoconstrictor to local anesthetic solutions has been endorsed as safe in the AAD guidelines. The local vasoconstriction minimizes serum levels of epinephrine, making a significant effect on placental vessels very unlikely [<a href="#rid26">26</a>]. Under the FDA's new pregnancy classification, epinephrine's "benefits outweigh risks during pregnancy; possible risk of teratogenicity based on limited or conflicting human data; risk of teratogenicity based on animal data at up to 30 times maximal recommended human dose; possible risk of decreased uterine perfusion based on drug's mechanism of action." However, the guidelines do caution to delay "urgent surgery" until the second trimester, if possible, and if "large amounts" of anesthesia are necessary, consultation with the patient's obstetrician should be made [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H521905466"><span class="h2">Wide local excision</span><span class="headingEndMark"> — </span>If a wide local excision is performed under local anesthesia, the same considerations about choice of local anesthesia hold, as discussed for the initial biopsy.</p><p>If a wide local excision is to be performed under general anesthesia, the procedure should be coordinated with the obstetrician, anesthesiologist, and neonatologist. Issues concerning the role of general anesthesia during pregnancy are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6775.html" rel="external">"Anesthesia for nonobstetric surgery during pregnancy"</a>.)</p><p class="headingAnchor" id="H627056287"><span class="h2">Sentinel lymph node biopsy</span><span class="headingEndMark"> — </span>If the pregnant patient is considered a candidate for sentinel lymph node biopsy (SLNB), there is controversy about the technique and timing of the procedure.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Technique</strong> – There is controversy about use of blue dye alone, use of a radiocolloid (technetium-99) alone, or use of both for SLNB. Some centers refrain from using blue dye due to risk for anaphylaxis [<a href="#rid27">27,28</a>]. Likewise, the European Society for Medical Oncology (ESMO) recommends avoidance of blue dye and the use of technetium-99 alone [<a href="#rid29">29</a>]. There is accumulating evidence that the radiation exposure to the fetus is minimal, even when the injection site is as close as 5 cm to the uterus [<a href="#rid27">27</a>]. Two small series have shown safety for the fetus when utilizing a radiocolloid alone, blue dye alone, or the combination [<a href="#rid30">30,31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing</strong> – The timing of SLNB is widely debated. Some advocate waiting until the second trimester to minimize exposure of the fetus to surgery and medication during pregnancy, especially during organogenesis. (See  <a class="medical medical_review" href="/z/d/html/7616.html" rel="external">"Evaluation and management of regional nodes in primary cutaneous melanoma", section on 'SLNB timing and technique'</a> and  <a class="medical medical_review" href="/z/d/html/7616.html" rel="external">"Evaluation and management of regional nodes in primary cutaneous melanoma"</a>.)</p><p></p><p class="bulletIndent1">In a European survey in which 290 questionnaires were completed by "melanoma physicians," almost half of respondents preferred to delay SLNB until after pregnancy [<a href="#rid9">9</a>]. This approach may be supported by a study that observed no difference in survival if the interval between wide local excision and SLNB was a median of 47 days [<a href="#rid32">32</a>]. The Yale Melanoma Unit supports this position, and recommends wide local excision under local anesthesia during pregnancy but delay of the SLNB until after delivery if general anesthesia is required [<a href="#rid33">33</a>]. However, at other institutions, this procedure is not delayed as it is viewed as important for staging, with SLNB performed during pregnancy in the second trimester and beyond [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1">If a wide local excision is to be performed under general anesthesia, the procedure should be coordinated with the obstetrician, anesthesiologist, and neonatologist. Issues concerning the role of general anesthesia during pregnancy are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6775.html" rel="external">"Anesthesia for nonobstetric surgery during pregnancy"</a>.)</p><p></p><p class="bulletIndent1">Another option suggested is to perform SLNB during pregnancy under local anesthesia, although this may be difficult in certain anatomic locations, such as deep nodes in the axilla close to the thoracodorsal nerve or deep nodes in the inguinal pelvic regions [<a href="#rid33">33</a>]. Complete lymph node dissections have been performed as well, if the SLNB is positive, without reported harm to the fetus or mother [<a href="#rid34">34</a>].</p><p></p><p class="headingAnchor" id="H3550480513"><span class="h2">Imaging studies</span><span class="headingEndMark"> — </span>In the case of a patient with advanced melanoma, imaging studies may be considered. According to a Committee Opinion Summary published by the American College of Obstetrics and Gynecologists' Committee on Obstetric practice, chest radiograph with appropriate shielding, ultrasonography, and magnetic resonance imaging (MRI; preferably without gadolinium) are the techniques of choice for imaging of the pregnant patient [<a href="#rid35">35</a>]. In addition, studies such as other radiography, computed tomography (CT) scan (without contrast), and nuclear medicine imaging studies can be utilized since they are typically administered at doses that do not lead to fetal harm [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/z/d/html/4791.html" rel="external">"Diagnostic imaging in pregnant and lactating patients"</a>.)</p><p class="headingAnchor" id="H2729794263"><span class="h2">Pathology</span></p><p class="headingAnchor" id="H2672132457"><span class="h3">Maternal tumor</span><span class="headingEndMark"> — </span>Some studies have suggested that melanomas diagnosed during pregnancy are more often of greater Breslow depth [<a href="#rid15">15,36,37</a>], but a larger proportion of studies have not observed a significant difference [<a href="#rid12">12-17,21</a>]. Likewise, a retrospective review analyzed both clinical and pathologic characteristics of 34 melanomas diagnosed during pregnancy and up to one year after delivery, and compared these with melanomas from age- and disease-matched controls. There was no significant difference in Breslow depth, ulceration, mitotic rate, stage of disease, anatomic location of the primary tumor, histologic subtype, Clark level, regression, necrosis, or vascular invasion [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H4176977165"><span class="h3">Placenta/fetus</span><span class="headingEndMark"> — </span>While melanoma is the most common cancer to metastasize to the fetus, metastasis across the placenta to the fetus is rare and is only observed in patients with widely metastatic disease [<a href="#rid39">39</a>]. Even if placental involvement with melanoma is identified, it has been estimated that the fetus is affected in only 25 percent of these cases [<a href="#rid40">40</a>]. In cases of maternal advanced disease, it is important to alert the pathologist to perform meticulous sectioning of the placenta since many sections may be needed to detect small foci of melanoma.</p><p class="headingAnchor" id="H1171296574"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>The general approach to the treatment of pregnancy-associated melanoma is based upon the same prognostic factors as for nonpregnant patients. (See  <a class="medical medical_review" href="/z/d/html/7620.html" rel="external">"Surgical management of primary cutaneous melanoma or melanoma at other unusual sites"</a>.)</p><p>Management becomes more complex once the need for SLNB is established or if the patient has more advanced disease, and should be individualized. In patients with advanced or metastatic melanoma, certain systemic agents may be teratogenic, such as combination BRAF (eg, <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">vemurafenib</a>, <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a>, <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">encorafenib</a>) plus MEK (eg, <a class="drug drug_general" data-topicid="105354" href="/z/d/drug information/105354.html" rel="external">cobimetinib</a>, <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">trametinib</a>, <a class="drug drug_general" data-topicid="118324" href="/z/d/drug information/118324.html" rel="external">binimetinib</a>) inhibitors and checkpoint inhibitor immunotherapy (eg, <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>, <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>) [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/z/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation"</a> and  <a class="medical medical_review" href="/z/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations"</a>.)</p><p>Patients receiving these agents should avoid lactation and pregnancy during and for variable periods of time after therapy is completed, based on the agent(s) used, as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combined BRAF plus MEK inhibitors</strong> – Patients receiving the combination of <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">vemurafenib</a> and <a class="drug drug_general" data-topicid="105354" href="/z/d/drug information/105354.html" rel="external">cobimetinib</a> should avoid pregnancy and lactation during therapy and for up to two weeks after the last dose of both agents.</p><p></p><p class="bulletIndent1">Those receiving the combination of <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a> plus <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">trametinib</a> should avoid pregnancy and lactation during therapy, up to two weeks after the last dose of dabrafenib <strong>and</strong> up to four months after the last dose of trametinib.</p><p></p><p class="bulletIndent1">Those receiving the combination of <a class="drug drug_general" data-topicid="118325" href="/z/d/drug information/118325.html" rel="external">encorafenib</a> plus <a class="drug drug_general" data-topicid="118324" href="/z/d/drug information/118324.html" rel="external">binimetinib</a> should avoid pregnancy during therapy, up to two weeks after the last dose of encorafenib <strong>and</strong> up to one month after the last dose of binimetinib. Those patients receiving this combination should also avoid lactation during therapy, up to three days after the last dose of binimetinib (based on the shorter half-life of this MEK inhibitor) <strong>and</strong> up to two weeks after the last dose of encorafenib.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Checkpoint inhibitor immunotherapy</strong> – Patients receiving checkpoint inhibitor immunotherapy should avoid lactation and pregnancy during therapy and up to three months after the last dose of <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>, during therapy and up to four months after the last dose of <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, and during therapy and up to five months after the last dose of <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>.</p><p></p><p class="headingAnchor" id="H2483877268"><span class="h2">Counseling</span></p><p class="headingAnchor" id="H340440901"><span class="h3">Future pregnancies</span><span class="headingEndMark"> — </span>A future pregnancy need not be delayed in a patient who has a thin localized melanoma with an excellent prognosis.</p><p>For a patient with more advanced disease, we recommend waiting at least two to three years before becoming pregnant since this is the time period in which recurrence is most likely [<a href="#rid42">42</a>]. However, this question should be addressed on a case-by-case basis since a patient later in her childbearing years may be concerned about her fertility if she defers pregnancy. The issue becomes even more controversial in a patient who has widespread disease because her life expectancy is unclear.</p><p>The physician must provide as much information as possible about prognosis and treatment to help guide the patient and her family to the best option.</p><p class="headingAnchor" id="H2924983672"><span class="h3">Oral contraceptives</span><span class="headingEndMark"> — </span>There does not appear to be an increased risk of melanoma from the use of estrogen-progestin contraceptives, even for long durations of use, so there is no reason to withhold this type of birth control in a patient who has been diagnosed with melanoma [<a href="#rid43">43</a>].</p><p>Many observational studies have assessed the risk of developing melanoma after oral contraceptive use, and the majority observed no effect when the patients who had ever used oral contraceptives were compared with controls who never used an oral contraceptive [<a href="#rid43">43</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>A pooled analysis that included 10 case-control studies and 3796 cases of melanoma in patients who had ever used oral contraceptives found no increased risk for melanoma when compared with 9442 controls who had never taken an oral contraceptive [<a href="#rid44">44</a>]. There was no relationship found between the risk of developing melanoma and duration of prior oral contraceptive use, age at first use, or past use of oral contraceptives, even in those who had taken oral contraceptives for extended periods of time. Similar results have been seen in subsequent observational studies [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>However, one prospective study involving 10 European countries demonstrated a borderline-significant association between use of oral contraceptives and risk of melanoma [<a href="#rid46">46</a>].</p><p></p><p class="headingAnchor" id="H203229693"><span class="h3">Hormonal replacement therapy</span><span class="headingEndMark"> — </span>Hormone replacement therapy (HRT) does not appear to increase the risk of melanoma and should not be withheld from a patient previously diagnosed with melanoma when no other reasonable alternative exists.</p><p>Compared with studies of melanoma and oral contraceptives, fewer studies have examined the relationship between HRT and melanoma. A majority of studies have not found an increased risk of melanoma from the use of HRT [<a href="#rid43">43</a>], but these studies have been mainly conducted in patients in the United States as opposed to Europe. These conflicting data may be related to the different formulations of estrogen utilized in Europe compared with the United States [<a href="#rid46">46</a>].</p><p>The largest body of evidence from the United States is from the Women's Health Initiative trial, which analyzed the incidence of melanoma in 27,347 postmenopausal females. The incidence of melanoma did not differ in those taking HRT (either in patients with an intact uterus who took estrogen with medroxyprogesterone or in those who had a hysterectomy and took estrogen alone) compared with a placebo group with a six-year follow-up period [<a href="#rid47">47</a>].</p><p>In contrast, multiple cohort studies conducted in Europe have demonstrated a modest increased risk in melanoma risk associated with menopausal hormone therapy [<a href="#rid46">46,48-50</a>].</p><p class="headingAnchor" id="H1300878660"><span class="h3">In vitro fertilization</span><span class="headingEndMark"> — </span>There is a paucity of high-quality data concerning the risk of melanoma associated with in vitro fertilization (IVF).One review did not observe a consistent association between IVF and malignant melanoma among all infertile patients. However, in ever-parous patients treated with IVF, the authors suggested there may be increased risk for melanoma [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H3810801956"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118501.html" rel="external">"Society guideline links: Melanoma screening, prevention, diagnosis, and management"</a>.)</p><p class="headingAnchor" id="H561294869"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with pregnancy-associated melanoma do not seem to have a worse prognosis than those with melanoma not diagnosed around the time of pregnancy. Their prognosis is based upon established prognostic factors. (See <a class="local">'Prognosis of pregnancy-associated melanoma'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A changing pigmented lesion during pregnancy that is clinically and dermatoscopically of concern as a possible melanoma should be biopsied immediately, as it would be in a nonpregnant patient. (See <a class="local">'Initial biopsy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The evaluation and treatment of the pregnant patient with melanoma should generally be similar to that of patients who are not pregnant. Special monitoring may be needed when performing wide local excision late in pregnancy, and the timing of sentinel lymph node biopsy may need to be altered. (See <a class="local">'Wide local excision'</a> above and <a class="local">'Sentinel lymph node biopsy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Melanomas in pregnant patients do not seem to have clinicopathologic characteristics that differ from the nonpregnant patient. While melanoma is the most common malignancy to metastasize to the fetus, it is still very rare and typically seen in patients with widely metastatic disease. (See <a class="local">'Pathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The patient with a thin melanoma with excellent prognosis need not delay future pregnancies or avoid use of oral contraceptives or hormone replacement therapy (HRT), if the latter are indicated. (See <a class="local">'Counseling'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Decision-making becomes much more complex in the patient with a more uncertain prognosis where a delay in future pregnancy may be considered, but this should be evaluated on a case-by-case basis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There are no conclusive data concerning in vitro fertilization (IVF) and risk of melanoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic agents used in advanced or metastatic melanoma may be teratogenic, such as combination BRAF plus MEK inhibitors and checkpoint inhibitor immunotherapy. Patients should avoid pregnancy and lactation during therapy and for variable periods of time after such therapy is completed, based on the agent(s) used. (See <a class="local">'Treatment'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lens M, Bataille V. Melanoma in relation to reproductive and hormonal factors in women: current review on controversial issues. Cancer Causes Control 2008; 19:437.</a></li><li><a class="nounderline abstract_t">Andersson TM, Johansson AL, Fredriksson I, Lambe M. Cancer during pregnancy and the postpartum period: A population-based study. Cancer 2015; 121:2072.</a></li><li><a class="nounderline abstract_t">PACK GT, SCHARNAGEL IM. The prognosis for malignant melanoma in the pregnant woman. Cancer 1951; 4:324.</a></li><li><a class="nounderline abstract_t">BYRD BF Jr, McGANITY WJ. The effect of pregnancy on the clinical course of malignant melanoma. South Med J 1954; 47:196.</a></li><li><a class="nounderline abstract_t">Neifeld JP, Lippman ME. Steroid hormone receptors and melanoma. J Invest Dermatol 1980; 74:379.</a></li><li><a class="nounderline abstract_t">Grill HJ, Benes P, Manz B, et al. Steroid hormone receptor analysis in human melanoma and non-malignant human skin. Br J Dermatol 1982; 107 Suppl 23:64.</a></li><li><a class="nounderline abstract_t">Mitkov M, Joseph R, Copland J 3rd. Steroid hormone influence on melanomagenesis. Mol Cell Endocrinol 2015; 417:94.</a></li><li><a class="nounderline abstract_t">Holtan SG, Creedon DJ, Haluska P, Markovic SN. Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Mayo Clin Proc 2009; 84:985.</a></li><li><a class="nounderline abstract_t">Ribero S, Longo C, Dika E, et al. Pregnancy and melanoma: a European-wide survey to assess current management and a critical literature overview. J Eur Acad Dermatol Venereol 2017; 31:65.</a></li><li><a class="nounderline abstract_t">Johansson AL, Andersson TM, Plym A, et al. Mortality in women with pregnancy-associated malignant melanoma. J Am Acad Dermatol 2014; 71:1093.</a></li><li><a class="nounderline abstract_t">Reintgen DS, McCarty KS Jr, Vollmer R, et al. Malignant melanoma and pregnancy. Cancer 1985; 55:1340.</a></li><li><a class="nounderline abstract_t">Slingluff CL Jr, Reintgen DS, Vollmer RT, Seigler HF. Malignant melanoma arising during pregnancy. A study of 100 patients. Ann Surg 1990; 211:552.</a></li><li><a class="nounderline abstract_t">McManamny DS, Moss AL, Pocock PV, Briggs JC. Melanoma and pregnancy: a long-term follow-up. Br J Obstet Gynaecol 1989; 96:1419.</a></li><li><a class="nounderline abstract_t">Wong JH, Sterns EE, Kopald KH, et al. Prognostic significance of pregnancy in stage I melanoma. Arch Surg 1989; 124:1227.</a></li><li><a class="nounderline abstract_t">MacKie RM, Bufalino R, Morabito A, et al. Lack of effect of pregnancy on outcome of melanoma. For The World Health Organisation Melanoma Programme. Lancet 1991; 337:653.</a></li><li><a class="nounderline abstract_t">Daryanani D, Plukker JT, De Hullu JA, et al. Pregnancy and early-stage melanoma. Cancer 2003; 97:2248.</a></li><li><a class="nounderline abstract_t">Tellez A, Rueda S, Conic RZ, et al. Risk factors and outcomes of cutaneous melanoma in women less than 50 years of age. J Am Acad Dermatol 2016; 74:731.</a></li><li><a class="nounderline abstract_t">Lens MB, Rosdahl I, Ahlbom A, et al. Effect of pregnancy on survival in women with cutaneous malignant melanoma. J Clin Oncol 2004; 22:4369.</a></li><li><a class="nounderline abstract_t">Lens M, Rosdahl I, Newton-Bishop J. Cutaneous melanoma during pregnancy: is the controversy over? J Clin Oncol 2009; 27:e11.</a></li><li><a class="nounderline abstract_t">O'Meara AT, Cress R, Xing G, et al. Malignant melanoma in pregnancy. A population-based evaluation. Cancer 2005; 103:1217.</a></li><li><a class="nounderline abstract_t">Stensheim H, Møller B, van Dijk T, Fosså SD. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol 2009; 27:45.</a></li><li><a class="nounderline abstract_t">Jones MS, Lee J, Stern SL, Faries MB. Is Pregnancy-Associated Melanoma Associated with Adverse Outcomes? J Am Coll Surg 2017; 225:149.</a></li><li><a class="nounderline abstract_t">Møller H, Purushotham A, Linklater KM, et al. Recent childbirth is an adverse prognostic factor in breast cancer and melanoma, but not in Hodgkin lymphoma. Eur J Cancer 2013; 49:3686.</a></li><li><a class="nounderline abstract_t">Cairncross ZF, Shack L, Nelson G, et al. Long-term Mortality in Individuals Diagnosed With Cancer During Pregnancy or Postpartum. JAMA Oncol 2023; 9:791.</a></li><li><a class="nounderline abstract_t">Kouba DJ, LoPiccolo MC, Alam M, et al. Guidelines for the use of local anesthesia in office-based dermatologic surgery. J Am Acad Dermatol 2016; 74:1201.</a></li><li><a class="nounderline abstract_t">Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol 2014; 70:401.e1.</a></li><li><a class="nounderline abstract_t">Crisan D, Treiber N, Kull T, et al. Surgical treatment of melanoma in pregnancy: a practical guideline. J Dtsch Dermatol Ges 2016; 14:585.</a></li><li><a class="nounderline abstract_t">Schwartz JL, Mozurkewich EL, Johnson TM. Current management of patients with melanoma who are pregnant, want to get pregnant, or do not want to get pregnant. Cancer 2003; 97:2130.</a></li><li><a class="nounderline abstract_t">Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 Suppl 6:vi160.</a></li><li><a class="nounderline abstract_t">Andtbacka RH, Donaldson MR, Bowles TL, et al. Sentinel lymph node biopsy for melanoma in pregnant women. Ann Surg Oncol 2013; 20:689.</a></li><li><a class="nounderline abstract_t">Mondi MM, Cuenca RE, Ollila DW, et al. Sentinel lymph node biopsy during pregnancy: initial clinical experience. Ann Surg Oncol 2007; 14:218.</a></li><li><a class="nounderline abstract_t">Oude Ophuis CM, Verhoef C, Rutkowski P, et al. The interval between primary melanoma excision and sentinel node biopsy is not associated with survival in sentinel node positive patients - An EORTC Melanoma Group study. Eur J Surg Oncol 2016; 42:1906.</a></li><li><a class="nounderline abstract_t">Broer N, Buonocore S, Goldberg C, et al. A proposal for the timing of management of patients with melanoma presenting during pregnancy. J Surg Oncol 2012; 106:36.</a></li><li><a class="nounderline abstract_t">Serrano-Ortega S, Buendía-Eisman A. [Melanoma and pregnancy]. Actas Dermosifiliogr 2011; 102:647.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists' Committee on Obstetric Practice. Committee Opinion No. 656: Guidelines for Diagnostic Imaging During Pregnancy and Lactation. Obstet Gynecol 2016; 127:e75.</a></li><li><a class="nounderline abstract_t">Travers RL, Sober AJ, Berwick M, et al. Increased thickness of pregnancy-associated melanoma. Br J Dermatol 1995; 132:876.</a></li><li><a class="nounderline abstract_t">Bannister-Tyrrell M, Roberts CL, Hasovits C, et al. Incidence and outcomes of pregnancy-associated melanoma in New South Wales 1994-2008. Aust N Z J Obstet Gynaecol 2015; 55:116.</a></li><li><a class="nounderline abstract_t">Fábián M, Tóth V, Somlai B, et al. Retrospective Analysis of Clinicopathological Characteristics of Pregnancy Associated Melanoma. Pathol Oncol Res 2015; 21:1265.</a></li><li><a class="nounderline abstract_t">Baergen RN, Johnson D, Moore T, Benirschke K. Maternal melanoma metastatic to the placenta: a case report and review of the literature. Arch Pathol Lab Med 1997; 121:508.</a></li><li><a class="nounderline abstract_t">Alexander A, Samlowski WE, Grossman D, et al. Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant. J Clin Oncol 2003; 21:2179.</a></li><li><a class="nounderline abstract_t">Xu W, Moor RJ, Walpole ET, Atkinson VG. Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature. Melanoma Res 2019; 29:333.</a></li><li><a class="nounderline abstract_t">Driscoll MS, Grant-Kels JM. Hormones, nevi, and melanoma: an approach to the patient. J Am Acad Dermatol 2007; 57:919.</a></li><li><a class="nounderline abstract_t">Gupta A, Driscoll MS. Do hormones influence melanoma? Facts and controversies. Clin Dermatol 2010; 28:287.</a></li><li><a class="nounderline abstract_t">Karagas MR, Stukel TA, Dykes J, et al. A pooled analysis of 10 case-control studies of melanoma and oral contraceptive use. Br J Cancer 2002; 86:1085.</a></li><li><a class="nounderline abstract_t">Donley GM, Liu WT, Pfeiffer RM, et al. Reproductive factors, exogenous hormone use and incidence of melanoma among women in the United States. Br J Cancer 2019; 120:754.</a></li><li><a class="nounderline abstract_t">Cervenka I, Al Rahmoun M, Mahamat-Saleh Y, et al. Exogenous hormone use and cutaneous melanoma risk in women: The European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2020; 146:3267.</a></li><li><a class="nounderline abstract_t">Tang JY, Spaunhurst KM, Chlebowski RT, et al. Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials. J Natl Cancer Inst 2011; 103:1469.</a></li><li><a class="nounderline abstract_t">Cervenka I, Al Rahmoun M, Mahamat-Saleh Y, et al. Postmenopausal hormone use and cutaneous melanoma risk: A French prospective cohort study. Int J Cancer 2019; 145:1754.</a></li><li><a class="nounderline abstract_t">Botteri E, Støer NC, Sakshaug S, et al. Menopausal hormone therapy and risk of melanoma: Do estrogens and progestins have a different role? Int J Cancer 2017; 141:1763.</a></li><li><a class="nounderline abstract_t">Simin J, Tamimi R, Lagergren J, et al. Menopausal hormone therapy and cancer risk: An overestimated risk? Eur J Cancer 2017; 84:60.</a></li><li><a class="nounderline abstract_t">Berk-Krauss J, Bieber AK, Criscito MC, et al. Melanoma risk after in vitro fertilization: A review of the literature. J Am Acad Dermatol 2018; 79:1133.</a></li></ol></div><div id="topicVersionRevision">Topic 109274 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18197460" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Melanoma in relation to reproductive and hormonal factors in women: current review on controversial issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25737403" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cancer during pregnancy and the postpartum period: A population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14821926" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The prognosis for malignant melanoma in the pregnant woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13146340" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The effect of pregnancy on the clinical course of malignant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6991607" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Steroid hormone receptors and melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6291573" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Steroid hormone receptor analysis in human melanoma and non-malignant human skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26415591" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Steroid hormone influence on melanomagenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19880689" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27231086" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pregnancy and melanoma: a European-wide survey to assess current management and a critical literature overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25440438" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Mortality in women with pregnancy-associated malignant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3971302" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Malignant melanoma and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2339917" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Malignant melanoma arising during pregnancy. A study of 100 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2620053" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Melanoma and pregnancy: a long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2802988" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prognostic significance of pregnancy in stage I melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1672000" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Lack of effect of pregnancy on outcome of melanoma. For The World Health Organisation Melanoma Programme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12712479" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pregnancy and early-stage melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26803345" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Risk factors and outcomes of cutaneous melanoma in women less than 50 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15514378" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effect of pregnancy on survival in women with cutaneous malignant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19470915" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cutaneous melanoma during pregnancy: is the controversy over?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15712209" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Malignant melanoma in pregnancy. A population-based evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19029418" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28457692" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Is Pregnancy-Associated Melanoma Associated with Adverse Outcomes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23932699" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Recent childbirth is an adverse prognostic factor in breast cancer and melanoma, but not in Hodgkin lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37022714" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Long-term Mortality in Individuals Diagnosed With Cancer During Pregnancy or Postpartum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26951939" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Guidelines for the use of local anesthesia in office-based dermatologic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24528911" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27240064" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Surgical treatment of melanoma in pregnancy: a practical guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12712462" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Current management of patients with melanoma who are pregnant, want to get pregnant, or do not want to get pregnant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23813932" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23054111" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Sentinel lymph node biopsy for melanoma in pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17066225" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Sentinel lymph node biopsy during pregnancy: initial clinical experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27266406" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The interval between primary melanoma excision and sentinel node biopsy is not associated with survival in sentinel node positive patients - An EORTC Melanoma Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22331751" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A proposal for the timing of management of patients with melanoma presenting during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21943875" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : [Melanoma and pregnancy].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26942391" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Committee Opinion No. 656: Guidelines for Diagnostic Imaging During Pregnancy and Lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7662565" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Increased thickness of pregnancy-associated melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25349945" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Incidence and outcomes of pregnancy-associated melanoma in New South Wales 1994-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26177701" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Retrospective Analysis of Clinicopathological Characteristics of Pregnancy Associated Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9167606" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Maternal melanoma metastatic to the placenta: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12775744" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30730328" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18021848" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Hormones, nevi, and melanoma: an approach to the patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20541681" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Do hormones influence melanoma? Facts and controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11953854" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A pooled analysis of 10 case-control studies of melanoma and oral contraceptive use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30814688" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Reproductive factors, exogenous hormone use and incidence of melanoma among women in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31506954" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Exogenous hormone use and cutaneous melanoma risk in women: The European Prospective Investigation into Cancer and Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21878677" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30671928" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Postmenopausal hormone use and cutaneous melanoma risk: A French prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28685818" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Menopausal hormone therapy and risk of melanoma: Do estrogens and progestins have a different role?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28783542" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Menopausal hormone therapy and cancer risk: An overestimated risk?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30055204" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Melanoma risk after in vitro fertilization: A review of the literature.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
